Introduction The consumption of antidepressants has increased considerably worldwide, including in Spain. Despite their effectiveness in cases of moderate to severe depression, their long-term use in mild cases is questioned. This study aims to evaluate the effectiveness of a deprescribing intervention in primary care, to reduce the unnecessary consumption of these drugs and improve patients' quality of life.
Material and Methods A community-based clinical trial will be carried out before and after in an adult population of residents of an urban area of Cadiz (Spain) who have been prescribed antidepressants in the last year. Participants will be randomly selected and followed up for a predetermined period after consensus.
The intervention will consist of a comprehensive evaluation of antidepressant treatment by a team of health professionals. Factors such as indication, dose, and response to treatment will be evaluated, and the Hamilton scale for anxiety and the Beck Inventory for depression will be used. In those cases where it is considered appropriate, a gradual reduction or suspension of the drug will be proposed, always under medical supervision.
Conclusions This research will contribute to generating scientific evidence on the safety and efficacy of deprescribing in primary care, promoting a more rational use of antidepressants, and improving the quality of life of patients. The results obtained could have important implications for clinical practice and for the development of clinical practice guidelines.

开始日期2025-04-01

申办/合作机构

Universidad De Huelva

NCT03329573

/ Completed临床1期

Randomized, Open Label, 2-way Crossover, Single Dose Bioequivalence Study of Paroxetine IR Tablets Manufactured in GSKT and Mississauga Sites in Healthy Chinese Participants Under Fasting and Fed Conditions

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) and paroxetine IR tablets have been approved for the treatment of three anxiety indications in China. This bioequivalence study will evaluate Paroxetine IR tablets manufactured in GSKT (A) and Mississauga (B) sites in healthy Chinese subjects under fasting and fed conditions to support the quality consistency evaluation. This is a single dose, open-label, randomized, two-period crossover study and will include a screening period (up to 7 days), two open-label treatment periods (up to 16 days) and a follow-up phase (up to 14 days after last-dose). The whole study will be divided into two groups, one for fasting condition enrolling approximately 36 subjects and another for fed condition for which approximately 44 subjects will be enrolled. In both groups, eligible subjects will be randomized to receive single dose of Paroxetine IR tablets A or B in a cross-over manner.

开始日期2018-05-30

申办/合作机构

GSK Plc

NCT01829919

/ Completed临床1期

Evaluation of Pharmacokinetics of Paroxetine Following Single and Repeat Oral Administration of Mesafem (7.5 mg Paroxetine Mesylate) Capsules in Healthy Postmenopausal Women

The purpose of this study is to assess the pharmacokinetics (absorption, breakdown and elimination from the body), safety and tolerability of Brisdelle (paroxetine mesylate) Capsules 7.5 mg when given as a single dose and multiple doses.

开始日期2011-07-01

申办/合作机构

Noven Therapeutics LLC

100 项与甲磺酸帕罗西汀相关的临床结果

登录后查看更多信息

100 项与甲磺酸帕罗西汀相关的转化医学

登录后查看更多信息

100 项与甲磺酸帕罗西汀相关的专利（医药）

登录后查看更多信息

7,681

项与甲磺酸帕罗西汀相关的文献（医药）

2026-12-01·Sleep medicine: X

Nocturnal sleep-related scratching disorder as a possible variant of NREM arousal disorder: Clinical features and polysomnographic study of four newly reported cases

Article

作者: Schenck, Carlos H ; Gómez Morales, María Fernanda ; Sinning, Nicole Cresp

A clinical variant of NREM arousal disorder is described manifesting with predominantly injurious, and exclusively sleep-related scratching without any conscious awareness, and without a history of dermatologic disease. Four patients were clinically evaluated and underwent videopolysomnography (vPSG). Case 1, a 30-year-old woman had a 20-yr history of non-injurious arm scratching/rubbing during sleep. vPSG: forearm rubbing against the chin during N2/N3. Two years later she developed restless bladder symptoms and leg movements before sleep onset. Serum ferritin level: 20.7 Intravenous iron therapy resulted in full control of bedtime leg movements, restless bladder symptoms, and nocturnal scratching. Case 2, a 28-year-old married man had a 1.5-yr history of perianal scratching with excoriations/bleeding during sleep, without other parasomnia. Medical and dermatologic evaluations were negative. vPSG: arousal index of 34/hr, with multiple episodes of perianal scratching. Paroxetine, 20 mg with clonazepam as (0.5-1.0 mg) at bedtime induced 50 % efficacy. Case 3, a 26-year-old African-American female had NREM parasomnias, vigorous sleep-related scratching with keloid formation, and major depression. Medical history was negative. vPSG: arousal index: 28/hr, without abnormal behaviors. Multiple sleep latency test (MSLT): mean sleep latency, 3.6 min, no REM sleep. Idiopathic hypersomnia and NREM parasomnias were diagnosed. Sleep-related scratching and NREM parasomnias responded fully to bedtime clonazepam, 0.5 mg. Case 4, a 50-year-old female had longstanding injurious sleep-related scratching, sleep terrors, and sleep bruxism. vPSG: 55 % sleep efficiency; arousal index: 25/hr, without abnormal behaviors or apneas. MSLT: no objective sleepiness. These cases of sleep-related scratching disorder represent a heterogeneous presumed variant of NREM arousal disorder with various comorbidities, and with full/partial control from diverse therapies.

2026-06-01·JOURNAL OF AFFECTIVE DISORDERS

Model-informed precision dosing of paroxetine to optimize individualized therapy in patients with mental disorders

Article

作者: Li, Yuqing ; Xia, Hui ; Wang, Zhanzhang ; Shang, Dewei ; Yan, Hui ; Guo, Zhihao ; Huang, Wanting

Paroxetine exhibits significant inter-individual variability in concentrations due to nonlinear pharmacokinetics and metabolic differences, particularly at higher doses. The therapeutic reference range recommended by the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP; 20-65 μg/L) was derived primarily from studies in patients receiving 20-40 mg daily, which may not adequately reflect drug exposure at higher clinical doses. This study integrated literature data analysis and population pharmacokinetic (PPK) simulations, revealing that the mean concentration reported in the literature was 173.13 μg/L at 60 mg/d, significantly exceeding the AGNP range, while PPK simulations indicated a mean concentration of 235.94 μg/L in females at 60 mg/d, nearly twice that in males. Considering that sex and dosage significantly influence paroxetine concentrations, sex-specific exploratory therapeutic reference ranges for 60 mg/d were proposed: 85-180 μg/L for males and 150-290 μg/L for females. Based on clinical data and reported toxicity cases, a laboratory alert concentration of 350 μg/L is suggested to ensure an adequate safety margin. Overall, this study refines the paroxetine therapeutic reference range by incorporating dose- and sex-specific guidance to support more precise therapeutic drug monitoring (TDM) and promote individualized treatment, particularly at a dosage of 60 mg.

2026-03-01·TALANTA

Implementation of an easy and cost-effective method for POCIS in situ calibration using o-DGT for pharmaceutical compounds

Article

作者: Monneron-Gyurits, Matthias ; Simon, Stéphane ; Martins de Barros, Rachel ; Lissalde, Sophie ; Buzier, Rémy ; Guibal, Robin ; Guibaud, Gilles ; Rougerie, Juliette

To address the lack of representativeness of sampling rate (R_s) for Polar Organic Chemical Integrative Sampler (POCIS) for water quality study using passive sampling, a novel approach was explored involving Diffusive Gradients in Thin film for organic compounds (o-DGT) as a calibration tool to determine site-specific R_s. In contrast to POCIS, effects of the diffusive boundary layer on water concentration (C_w) determination can be considered for o-DGT. In this approach, o-DGT and POCIS, with similar Oasis® HLB binding phases and polyether sulfone membranes, were exposed under identical conditions. The underlying hypothesis is that both devices will yield the same C_w. Based on this, R_s can be calculated from the masses accumulated by the two devices and the o-DGT calibration parameters. In controlled lab conditions, this study demonstrated the consistency of R_s determined by o-DGT with conventional experimental methods across various hydrodynamic conditions. During field deployments, the limitations of R_s determined by the usual methods were highlighted: C_w sometimes too low for quantification by grab sampling, high uncertainty and strong desorption of Performance Reference Compound (PRC) due to the hydrodynamic conditions. Conversely, the R_s obtained by o-DGT were systematically determined and within the same magnitude as those determined by other available methods. The advantages of this method lie in the readily available o-DGT parameters for each deployment condition and in the measurement of C_w which can be challenging. This calibration method allows to determine site-specific R_s easily and at a low cost. In the context of monitoring programs, deploying o-DGT during initial campaigns could facilitate R_s determination under specific environmental conditions, which can then be applied to subsequent campaigns. Nevertheless, for compounds with low affinity for o-DGT, as Paroxetine, the proposed method is limited to obtain robust R_s.

项与甲磺酸帕罗西汀相关的新闻（医药）

2026-02-13

·微信

一文解析国内外玫瑰痤疮药物治疗指南差异及优化策略

玫瑰痤疮是一种好发于面中部的慢性炎症性皮肤病，临床症状包括持续性红斑、阵发性潮红、丘疹脓疱等。全球约5.5%的成年人受到玫瑰痤疮的影响，生活质量明显下降。由于临床表现复杂，治疗存在困难与挑战。目前，玫瑰痤疮的治疗以药物为主，各国诊疗方案不尽相同，因此，对玫瑰痤疮的诊疗指南共识进行总体比较有助于了解国内外的治疗现状，汲取各国针对不同患者在治疗选择上的宝贵经验。本文根据各文献整理了国内外针对玫瑰痤疮的指南共识（表1），并基于指南共识中表型与证据的分层推荐建议，对玫瑰痤疮的药物治疗进行以下综述，并进一步探讨最新的玫瑰痤疮药物治疗进展。表1 国内外玫瑰痤疮诊疗指南和共识注：a美国痤疮与玫瑰痤疮协会（American Acne and Rosacea Society，AARS）；b美国国家玫瑰痤疮协会（National Rosacea Society，NRS）玫瑰痤疮治疗目标与原则玫瑰痤疮是一种慢性复发性疾病，突出特点为诱发加重和缓解的循环过程。各国指南共识对玫瑰痤疮的治疗目标接近，即：缓解或消除临床症状、最大程度清除皮损；最大限度地减少疾病对患者生活质量的影响；最大限度地延长疾病复发时间；最大限度地提高患者对治疗的满意度。为了最大程度清除皮损且减少患者的复发频率，玫瑰痤疮患者日常生活方式的管理和皮肤护理受到重视。指南建议玫瑰痤疮患者应该注重个人生活方式，及时识别和避免疾病的诱发因素，包括日光照射、温度变化、睡眠不足、压力焦虑情绪等。美国玫瑰痤疮协会（American Acne and Rosacea Society，AARS）共识指出避免阳光照射等诱发因素相较于药物治疗对玫瑰痤疮潮红症状的价值更高。日常皮肤护理的目标是保持皮肤屏障的完整性，同时避免使用不耐受的药物或护肤品，合理防晒，温和清洁皮肤等。玫瑰痤疮治疗分类目前加拿大等国家将玫瑰痤疮进行亚型分类并提出相应治疗方案。各国的亚型分类不尽相同，大致包括以下几个：红斑毛细血管扩张型（erythematotelangiectatic rosacea，ETR）；丘疹脓疱型（papulopustular rosacea，PPR）；鼻赘型（phymatous rosacea）; 眼型（ocular rosacea）；肉芽肿型玫瑰痤疮（granulomatous rosacea，GR）；爆发型玫瑰痤疮； Morbihan氏病等。 AARS共识建议玫瑰痤疮的管理从亚型向表型转变，其表型分类包括短暂或持续的面中部红斑、毛细血管扩张、炎性皮损、肥厚增生改变和眼部症状，次要表现包括灼热、刺痛等，荷兰等国均重点强调了以表型分类的治疗策略。西班牙共识虽未明确表型分类，但其药物治疗部分依据持续性红斑、一过性红斑及毛细血管扩张等表型给予了相应建议。英国指南虽提及表型分类，但是强调了传统分类方式对患者体征的重视并具备更高的临床试验、临床场景适配度的优势。相较于表型或亚型的分类，部分指南共识采用基于治疗方式提供指导意见，较为全面地覆盖各种症状。中国共识对治疗方式分类的阐述最为详实，相较其他指南涵盖了手术治疗、注射疗法及针对不同皮损表现的联合治疗方案。此外，AARS强调了针对PPR的外用药联合治疗策略，德国指南重点阐述了玫瑰痤疮治疗药物的超适应证用法。玫瑰痤疮药物选择玫瑰痤疮药物治疗主要包括局部用药、系统用药等。依据各国指南共识，基于药物证据等级和推荐强度，玫瑰痤疮药物选择如下表2。表2 各国玫瑰痤疮指南/共识药物推荐对比表一线治疗局部用药针对丘疹脓疱（1）伊维菌素伊维菌（ivermectin，IVM）是阿维菌素的半合成衍生物，是寄生虫病的治疗或预防药物。伊维菌素的大环内酯结构具有抗炎作用，同时其强烈的神经毒性可消除玫瑰痤疮的蠕形螨。指南推荐：多国指南推荐1%IVM乳膏作为一线用药治疗PPR（高证据等级/一致推荐）。荷兰和美国同时推荐IVM用于持续性红斑。美国国家玫瑰痤疮协会（National Rosacea Society，NRS）共识提及IVM 在潮红中的潜在应用价值。 2017和2019版全球共识将IVM、甲硝唑和壬二酸同时列为PPR的一线用药，并强调了IVM在重度皮损患者中的应用价值。西班牙共识也指出IVM在重度患者治疗中的优势，表明其效力随时间推移而提高。部分指南因IVM费用较高、未上市或多地未参保及临床数据匮乏将其列为二线治疗药物。除局部使用IVM外，瑞士指南和澳大利亚/新西兰共识指出口服IVM可作为重度丘疹脓疱的二线治疗方案。（2）甲硝唑甲硝唑具有抗菌和抗寄生虫的双重功效，是治疗玫瑰痤疮最常用的局部药物，安全性高、副作用小。指南推荐：甲硝唑在国内及英国、西班牙、瑞士、德国等国被一致推荐为治疗丘疹脓疱的一线外用药（高证据等级/一致推荐）。各国指南推荐使用甲硝唑的剂量和剂型不尽相同，但以0.75%乳膏或凝胶最常见，也可见霜剂和乳剂，多数指南共识推荐浓度介于0.75%～1%。在加拿大、荷兰等国其推荐等级较低，次于外用IVM（尤其是重度丘疹脓疱），但提示其在维持治疗期间降低炎性皮损复发的效果较好。部分指南指出0.75%～1%甲硝唑乳膏或凝胶对红斑也有一定的疗效。（3）壬二酸壬二酸是一种饱和二羧酸，具有抗炎、抗菌及调节角化的作用，广泛应用于PPR的一、二线治疗，以及重度患者的维持治疗。指南推荐：其中15%壬二酸凝胶认可度最高，国内推荐10%、20%的乳膏或凝胶，美国批准15%壬二酸泡沫剂型。尽管壬二酸是多国的一线用药，但在西班牙共识中壬二酸的推荐等级低于甲硝唑和IVM，并作为PPR的二线治疗药物, 强调其在疾病维持治疗中的优势。中国等国也将其作为二线治疗药物。荷兰等国推荐其为红斑的二线治疗药物，其中瑞士推荐使用15%壬二酸乳膏或凝胶治疗面部红斑。针对红斑、潮红，外用缩血管类药物（1）溴莫尼定溴莫尼定是一种高度选择性的α2-肾上腺素能受体激动剂，可直接作用于玫瑰痤疮病理性扩张的真皮小动脉，使红斑消失，但其对扩张的毛细血管无效。指南推荐：各国普遍推荐使用溴莫尼定的凝胶剂型，浓度介于0.33％～1％之间，以0.5%和0.33%浓度最常见。欧洲药品管理局（EMA）批准0.33%的溴莫尼定凝胶用于成人玫瑰痤疮对症治疗。因其起效迅速、作用持久的特点，美国等多国推荐溴莫尼定凝胶作为持续性红斑的一线用药（高证据等级/一致推荐）。加拿大等国因其价格昂贵、用药或停药后可能出现红斑恶化反应，将溴莫尼定列为持续性红斑的二线治疗。少数国家将其列为玫瑰痤疮潮红的一线用药（0.5%，1次/d）。目前国内尚无0.5%溴莫尼定凝胶上市。（2）羟甲唑啉羟甲唑啉是一种选择性α1A肾上腺素受体激动剂，具有血管收缩和抗炎特性，FDA批准其为治疗玫瑰痤疮的外用缩血管药物。指南推荐： 2019版全球共识、NRS共识等推荐其为持续性红斑的一线用药。澳大利亚/新西兰共识推荐其为潮红的一线用药。中国等指南将其作为红斑的二线治疗。由于证据有限，2019版ROSCO共识提出移除局部使用α肾上腺能调节剂和口服β受体阻滞剂治疗玫瑰痤疮潮红的建议。系统用药针对丘疹脓疱、鼻赘（1）多西环素口服抗生素是治疗玫瑰痤疮中重度丘疹脓疱的一线方案。其中低剂量多西环素（40mg缓释剂型）受国内外广泛认可。 40mg缓释制剂是由30mg即刻释放剂和10mg缓释剂组成的盖伦制剂，生物利用度显著不同，不具备抗菌作用而表现为显著的抗炎活性，故被称为“亚抗菌剂量”，能有效减轻传统抗生素导致的光敏感、色素沉着、胃肠道不适等副作用。指南推荐：目前美国等国推荐其为中重度PPR的一线治疗方案。较于40mg缓释剂，部分国家也批准使用价格低廉的50/100/200mg多西环素、红霉素、克拉霉素等药物。而英国只批准多西环素的缓释制剂用于丘疹脓疱的治疗。加拿大由于多西环素的药物可及性其推荐等级略低。瑞士等国同时推荐多西环素作为玫瑰痤疮活动期鼻赘的一线治疗方案。中国等国推荐其也可用于治疗面部持续性红斑，但由于经济成本过高、副作用大故谨慎推荐。加拿大指南指出，虽多西环素治疗玫瑰痤疮红斑存在高等级证据，但研究群体为炎性皮损背景下的红斑患者，其对红斑的疗效可能是脓疱丘疹病灶周围炎症反应减退的表现。（2）异维A酸异维A酸是一种强效的维生素A衍生物，其可减少皮脂腺分泌、调节皮肤角化、减少皮肤炎症反应，但有致使皮肤干燥、光敏性增加、肝功能和血脂异常等副作用，故在玫瑰痤疮治疗中低剂量间歇给药受到重视。指南推荐：多国指南共识推荐口服异维A酸作为难治性、复发性玫瑰痤疮中重度丘疹脓疱的一线治疗方案。荷兰指南表明，当口服多西环素或米诺环素8~12周后患者丘疹脓疱皮损未改善时，应更换低剂量异维A酸（0.25~0.35mg/kg）治疗12～16周，加拿大指南也建议将异维A酸作为多西环素或米诺环素疗效不佳的替代治疗。德国指南一致推荐低剂量异维A酸（0.1～0.3mg/kg）的系统治疗。澳大利亚/新西兰共识的推荐剂量为5～10mg/d。瑞士指南综合临床经验提出更低剂量异维A酸（0.15mg/kg）治疗仍有效。部分指南考虑药物证据等级差异以及皮肤黏膜干燥、致畸和肝功能损伤等不良反应，将异维A酸列为丘疹脓疱的二线用药。中国等国指南及全球共识一致推荐其为PhR的一线用药，尤其是活动期炎症性鼻赘改变。使用过程中应注意不良反应的发生，包括唇炎、干眼症、结膜炎、鼻干燥、鼻出血和刺激性皮炎等。针对丘疹脓疱、红斑羟氯喹羟氯喹主要被用于治疗系统性红斑狼疮、类风湿性关节炎等自身免疫性疾病，具有抗炎、抗免疫及抗紫外线损伤的作用。推荐指南：国内一致推荐其作为治疗红斑的系统用药（0.1g～0.2g，2次/d），也推荐治疗丘疹脓疱。澳大利亚/新西兰共识将其作为丘疹脓疱和红斑潮红的替代治疗方案（200mg/d），其余未对该药进行详尽说明。 ROSCO指出同为抗疟药的复方新诺明对丘疹脓疱也有一定的疗效。二线及替代治疗主要针对丘疹脓疱（1）克林霉素和红霉素克林霉素和红霉素作为常见抗生素常以凝胶或乳膏剂型外用治疗PPR。推荐指南：国内推荐0.3%或1%克林霉素乳膏或凝胶、2%红霉素乳膏作为PPR的二线治疗。德国指南将1%克林霉素乳膏列入超适应证疗法，表明应尽量减少外用以避免致敏和耐药。荷兰也不建议单独或与维A酸联合外用克林霉素，但瑞士仍肯定1%克林霉素/5%过氧化苯甲酰复合凝胶对丘疹脓疱的疗效。口服克林霉素或红霉素的推荐等级不高，部分仅将其作为多西环素过敏者或不耐受者的替代用药。（2）过氧化苯甲酰过氧化苯甲酰因其抗菌作用被用于治疗玫瑰痤疮。推荐指南：国内推荐过氧化苯甲酰点涂用于治疗鼻部或口周丘疹脓疱。瑞士建议5%过氧化苯甲酰/克林霉素凝胶用于治疗PPR，并提及在爆发型玫瑰痤疮中的潜在价值。由于其刺激性较强，易引起局部红斑、瘙痒、鳞屑等不良反应，故应用于皮肤屏障较完善的耐受者，该建议在中国和荷兰两国的指南中保持一致。（3）维A酸基于抗炎和角质溶解的作用，维A酸类药物如阿达帕林、0.025%的维甲酸被瑞士、美国等指南推荐为PPR的二线用药。加拿大等推荐外用维A酸可缓解玫瑰痤疮相关增生肥大的风险且费用低于手术治疗。（4）水杨酸水杨酸具备角质调节和抗菌抑菌作用，国内提出其对PPR治疗有效，但多国指南中未描述水杨酸的应用，且德国指出玫瑰痤疮患者应避免使用含水杨酸、乙醇酸等刺激性成分的产品。系统用药针对丘疹脓疱、红斑米诺环素米诺环素是一种半合成四环素类抗生素，具有抗炎、抗菌、抗肉芽肿形成和收缩血管的功效。推荐指南：国内推荐其作为重度PPR的首选药，也可治疗中重度红斑（NRS也提及可治疗中重度红斑，但证据等级和推荐等级低）。西班牙与荷兰推荐米诺环素100mg/d作为中重度PPR的二线治疗。美国共识指出米诺环素联合多西环素可用于治疗PhR。英国等国考虑其导致自身免疫性肝炎、药物诱发的系统性红斑狼疮、超敏反应综合征等罕见且严重的副作用，不推荐用于PPR，而更倾向多西环素或异维A酸。针对红斑、潮红非选择性β肾上腺素受体抑制剂可通过阻断皮肤血管平滑肌上的β受体收缩血管，亦可作用于心肌β受体以降低心率和缓解焦虑，从而用于治疗患者持续性红斑及潮红。常用来治疗玫瑰痤疮的β肾上腺素受体抑制剂为卡维地洛、普萘洛尔。（1）卡维地洛卡维地洛是一种α1、β1和β2受体拮抗剂，同时具有抗氧化和抗炎特性。推荐指南：由于目前临床证据等级较低，德国等国推荐作为红斑和潮红的二线用药，国内推荐作为红斑的二线用药，瑞士等推荐作为潮红的二线用药。（2）普萘洛尔相比卡维地洛，研究表明普萘洛尔产生的低血压、心动过缓等副作用较明显，故瑞士等国不推荐使用。推荐指南：美国等国针对难治性持续性红斑及玫瑰痤疮潮红仍考虑使用普萘洛尔。英国则只推荐使用普萘洛尔而未提及卡维地洛。 β肾上腺素受体抑制剂普遍存在证据等级较低和各国意见不一致的问题，2019版ROSCO共识已不推荐其作为持续性红斑和阵发性潮红的治疗方案，其临床应用有待进一步观察。相较于国内指南，国外还提及的药物包括治疗丘疹脓疱的磺胺醋酰钠和亚硫酸氢盐、硫酸锌，治疗GR的免疫抑制剂吡美莫司、他克莫司，治疗活动期鼻赘型玫瑰痤疮的甲氧苄啶/复方磺胺甲噁唑（仅用于联合治疗）等。药物最新进展玫瑰痤疮新型药物及药物超适应证用法的研究逐渐弥补了传统药物对红斑、潮红等表型治疗方案的空缺，不仅有望为患者带来更高效精准的治疗方案，还可能克服现有药物应用的局限性、减少不良反应发生等。神经精神类药物（1）帕罗西汀玫瑰痤疮是一种心身疾病，研究表明52.3%的患者睡眠质量差，且罹患焦虑或抑郁症的风险为普通人的2～3倍。国内研究使用帕罗西汀等用于焦虑紧张的患者以缓解面部灼热、瘙痒刺痛症状，与AARS的建议一致。一项为期12周的多中心、双盲、安慰剂随机对照试验表明，接受帕罗西汀25mg/d的患者临床红斑评估缓解率明显高于安慰剂组，次要结局中总体潮红水平、灼热感、抑郁程度都得到改善。（2）加巴喷丁目前针对ETR常用的治疗药物为卡维地洛，改善血管扩张，从而治疗难治性阵发性潮红和持续性红斑。研究循证：一项纳入315例患者为期12周的随机对照非劣性试验比较了加巴喷丁（300mg，3次/d）和卡维地洛（5mg，2次/d）治疗ETR的效能。结果显示，第12周加巴喷丁组和卡维地洛组在CEA评分上均有效且无明显差别。相比卡维地洛，加巴喷丁改善面部潮红更显著，这与Li等的研究结果一致。一项随机对照试验比较了不同剂量加巴喷丁（200mg或300mg，3次/d）的疗效。结果表明，与安慰剂对照相比，CEA评分无显著差异。基于现有研究，加巴喷丁在治疗玫瑰痤疮潮红症状上体现出显著优势，但其对面部持续性红斑的治疗及生活质量改善还需要更多的研究。噻吗洛尔外用噻吗洛尔因其具有抗血管生成和收缩血管的作用而受到重视。研究循证： Tsai等采用半脸研究对8名患者进行了为期16周的局部0.5%噻吗洛尔凝胶治疗。结果表明，12周时红斑显著改善。一篇研究采用0.5%噻吗洛尔滴眼液处理一侧面部，与对侧相比，患者CEA和PSA评分得到显著改善。该药目前相关研究报道较少，均采用半脸试验，仍需要进一步扩大临床研究。生物制剂（1）降钙素基因相关肽受体抑制剂降钙素基因相关肽（calcitonin gene-related peptide，CGRP），是一种在偏头痛中起重要作用的神经肽，可引起血管扩张和神经炎症，越来越多研究表明CGRP与玫瑰痤疮的发生发展相关，在治疗玫瑰痤疮潮红和红斑中作用显著。研究循证：在一项为期20周的非随机对照试验中，30d受试者每4周皮下注射CGRP单抗140mg。结果表明，患者中重度潮红平均天数较基线水平减少了6.9d，中重度红斑平均天数较基线水平减少了8.1d。一项针对合并偏头痛症状的玫瑰痤疮患者的回顾性研究表明，在接受CGRP单抗治疗期间54%患者丘疹脓疱得以改善，23%患者丘疹脓疱病情稳定，8%患者眼部症状得以改善。有研究基于真实世界数据评估了18岁以上患者的玫瑰痤疮发病率。结果表明，与相匹配的曲普坦类药物组和托吡酯组相比，CGRP单抗组玫瑰痤疮的发病率显著降低。 CGPR单抗的副作用常包括注射部位出现疼痛、肿胀及伴发的丘疹、荨麻疹，部分患者出现便秘、恶心、呕吐等胃肠道不适症状。CGRP在保护性血管舒张、促血管生成、氧化应激和体内平衡中具有潜在保护作用，阻断CGRP可能会加重血管疾病和缺血。近期中风、不稳定型心绞痛或有卒中、心肌梗死病史的患者应慎用CGRP单抗。（2）司库奇尤单抗司库奇尤单抗是一种重组人源单克隆IgG1/κ抗体，能够特异性结合IL-17。研究循证：在Kumar等的研究中，17例中重度PPR患者接受了每周300mg司库奇尤单抗的皮下注射治疗，持续5周后，将剂量减少至每月300mg皮下注射，并继续治疗2个月。结果显示，16周后患者的丘疹脓疱数量显著减少，虽然红斑改善不明显，但IGA、GFSS和RosQoL评分均较治疗前显著改善。这表明司库奇尤单抗可能是治疗中重度PPR的一种有效选择。除常见的注射部位出现疼痛肿胀外，司库奇尤单抗可能会增加感染的风险，如鼻咽炎、念珠菌感染、上呼吸道感染等。少数患者会出现转氨酶升高等肝功能异常和严重的过敏反应。 JAK抑制剂目前临床常见的JAK抑制剂有托法替尼、乌帕替尼和阿布昔替尼等。研究循证：在一项纳入21例口服托法替尼（初始剂量5mg，2次/d；症状好转后改为5mg，1次/d或隔日1次）的玫瑰痤疮患者的回顾性研究中，15例患者面部红斑明显消退（IGA≤1）。研究报道了两例口服乌帕替尼（15mg，1次/d）和四例口服阿布昔替尼（100mg，1次/d）的难治性玫瑰痤疮患者的案例。结果表明接受乌帕替尼治疗的患者在48h内包括红斑、潮红等症状得到显著改善，而使用阿布昔替尼治疗者症状改善程度不一致。 Ren等报告了1例阿布昔替尼（100mg，1次/d）成功治疗GR的案例。 JAK抑制剂治疗难治性玫瑰痤疮显现出独特优势，但其长期使用的安全性、和有效性仍需通过大量RCT试验进行验证。JAK抑制剂的副作用包括但不限于感染（如带状疱疹、上呼吸道感染、流感样疾病、口腔疱疹）、恶性肿瘤风险增加、心血管事件（如血栓形成、心脏相关事件），其中毛囊炎因其临床显著性受到关注。一项系统评价表明，使用JAK抑制剂诱发毛囊炎的发生率为2%～10%。雷帕霉素雷帕霉素是一种mTORC1特异性抑制剂，参与调节一系列细胞信号的转导。一项纳入18例患者的随机对照、安慰剂试验表明，局部应用雷帕霉素治疗（2次/d）连续4周后患者CEA和IGA评分均显著降低。中西医结合治疗青蒿素及其衍生物青蒿素及其衍生物是从中国传统植物黄花蒿中提取的天然产物，研究表明其拥有抗炎和抗血管生成的活性。研究循证：在一项130例玫瑰痤疮患者的随机对照实验中，外用1%蒿甲醚乳剂4周对丘疹脓疱的改善优于外用3%甲硝唑乳剂，且前者维持治疗效果更佳、疾病复发比例显著降低。甘草酸二铵是从甘草中提取的有效单体成分，具有广泛的抗炎、抗氧化、抗过敏和免疫调节作用。一项纳入117例玫瑰痤疮患者的RCT研究表明其对PPR疗效佳。凉血解毒汤凉血解毒汤（桑白皮、黄芩、栀子、金银花等）有清肺胃热、解毒凉血的功效，研究表明其可显著改善玫瑰痤疮患者的皮损、中医症候和生活质量。同时，凉血解毒汤联合散刺放血或窄谱强脉冲光也取得了良好的疗效。虽中药具有重要潜力，但作其肝肾负担等副作用不能忽视。需对中药进行活性分析并提取有效活性物质以达到针对玫瑰痤疮表型的精准治疗。小结玫瑰痤疮表型多样，临床治疗仍面临诸多挑战，难以使患者满意。虽然各国的药物及治疗选择存在差异，但是以药物为主的综合治疗方案仍是国内外玫瑰痤疮治疗的主要原则。随着对疾病发病机制的深入研究，未来玫瑰痤疮趋向精准诊疗，并注重患者个体化的全程管理。参考文献： [1]罗宏杰,宋德宇,蒋献,张璐.国内外玫瑰痤疮药物治疗指南差异及优化策略：基于表型与证据的分层推荐[J].中国皮肤性病学杂志,2026,40(01):7-16.DOI:10.13735/j.cjdv.1001-7089.202503011. [2] Dirr MA,Ahmed A,Schlessinger DI,et al.Rosacea core domain set for clinical trials and practice:a consensus statement[J].JAMA Dermatol,2024,160(6):658-666. [3] Clanner-Engelshofen BM,Bernhard D,Dargatz S,et al.S2k guideline:rosacea[J].J Dtsch Dermatol Ges,2022,20(8):1147-1165. [4] 中华医学会皮肤性病学分会玫瑰痤疮研究中心，中国医师协会皮肤科医师分会玫瑰痤疮专业委员会.中国玫瑰痤疮诊疗指南(2021版)[J].中华皮肤科杂志，2021,54(4):279-288.Rosacea Research Center,Chinese Society of Dermatology,Rosacea Professional Committee,Chinese Dermatologist Association.Guidelines for the diagnosis and treatment of rosacea in China (2021 edition)[J].Chin J Dermatol,2021,54(4):279-288. [5] Hampton PJ,Berth-Jones J,Duarte Williamson CE,et al.British association of dermatologists guidelines for the management of people with rosacea 2021[J].Br J Dermatol,2021,185(4):725-735. [6] Van Zuuren EJ,Van Der Linden MMD,Arents BWM.Rosacea treatment guideline for the Netherlands[J].Br J Dermatol,2020,182(6):1504-1506. [7] Anzengruber F,Czernielewski J,Conrad C,et al.Swiss S1 guideline for the treatment of rosacea[J].J Eur Acad Dermatol Venereol,2017,31(11):1775-1791. [8] Asai Y,Tan J,Baibergenova A,et al.Canadian clinical practice guidelines for rosacea[J].J Cutan Med Surg,2016,20(5):432-445. [9] Rademaker M,Foley P,Sullivan J,et al.Pharmaceutical management of rosacea—an Australian/New Zealand medical dermatology consensus narrative[J].Dermatol Ther,2024,2024(1):9678447. [10] Thiboutot D,Anderson R,Cook-Bolden F,et al.Standard management options for rosacea:the 2019 update by the National Rosacea Society Expert Committee[J].J Am Acad Dermatol,2020,82(6):1501-1510. [11] Oliveira CMM,Almeida LMC,Bonamigo RR,et al.Consensus on the therapeutic management of rosacea-Brazilian society of dermatology[J].An Bras Dermatol,2020,95(Suppl 1):53-69. [12]其他略. 推荐阅读皮肤科外用药正确使用指南半生白斑，半年复色：他用28年找回完整的自己 🧧新年接福！点击领取新年专属红包声明：皮科在线原创内容版权均属皮科在线所有。转载文章或“皮科在线”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场。授权转载时须注明来源。如果存在侵权、或不希望被转载的媒体或个人可与我们联系进行删除处理。

2026-02-12

·搜狐新闻

采用MonolixSuite软件发表的部分参考文献汇总（2024年7月-2025年12月）

采用MonolixSuite软件发表的部分参考文献汇总（2024年7月-2025年12月）导读凡默谷技术部挑选了2024年7月—2025年12月全球采用MonolixSuite软件发表或涉及MonolixSuite综述的部分应用文章。希望对您的业务或专业学习有所帮助。本公众号不提供文章的原文下载，如您想了解某篇文章的详情，请下载《采用MonolixSuite软件发表的部分参考文献汇总列表 2024年7月-2025年12月》PDF版文件，有对应文章的介绍链接。2024年7月-2025年12月 PDF版文献汇总列表下载(复制链接到浏览器）https://www.jianguoyun.com/p/DfVhFxUQ_a64Bxih9ZkGIAA访问密码：HdX0tA01中国用户发表的部分文章或涉及到的综述用于预测拓扑异构酶抑制剂ADC药物在小鼠及人体内的药代动力学、肿瘤生长抑制效应及毒性风险的 PBPK-PD 模型PBPK-PD model for predicting pharmacokinetics, tumor growth inhibition, and toxicity risks of topoisomerase inhibitor ADCs in mice and humans西维来司他钠在中国重症肺炎患者中的群体药代动力学研究Population pharmacokinetics of sivelestat in Chinese patients with severe pneumoniaZhang X., Hu H., Li Z., Zhang P., Pan L., Wang L., Mao J., Li F., Zhang L. Fundamental and Clinical Pharmacology. 2025 39:2 Article Number e70001亚胺培南在感染性实体瘤患者中的群体药代动力学：一项真实世界研究Population pharmacokinetics of imipenem in solid tumor patients with infections: A real-world studyXu T., Zou T., Zhang J., Li Z., Li F., Du J., Hao Z. Journal of Global Antimicrobial Resistance. 2025 45 (107-114)PopPK和PBPK模型指导美罗培南在重症患儿增强肾脏清除率下的剂量优化PopPK and PBPK Models Guide Meropenem Dosing in Critically Ill Children with Augmented Renal ClearanceLiu Y., He H., Zhang S.-S., Zhou J., Zhu J.-W., Xu J., Miao H.-J., Chen J.-H., Hao K. Pharmaceutics. 2025 17:12 Article Number 1544达泊西汀在健康中国男性受试者中的群体药代动力学Population Pharmacokinetics of Dapoxetine in Healthy Chinese Male SubjectsPu L., Wu T., Bai F., Lu H., Wang Y., Gao Y., Qiu W. Journal of Clinical Pharmacology. 2025丙泊酚注射液的群体药代动力学研究进展陈浩，陈建恒，吕洁，严泽林，卞民亮，陆程灿.《临床药物治疗杂志》. 第24 卷第1 期, 2026年1月02其他国家用户发表的部分文章或相关的综述基于模型的荟萃分析应用 MonolixSuite：针对纵向分类与连续数据的教程Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous DataBracis C., Taneja A., Lyauk Y.K., Barcomb H., de la Peña A., Cellière G.CPT: Pharmacometrics and Systems Pharmacology2026 15:2 Article Number e70158 高强度间歇性运动对二甲双胍在健康男性的药代动力学影响——基于PopPK模型的评估Effect of high-intensity interval exercise on metformin pharmacokinetics in healthy men, assessed through a population pharmacokinetic modelNikolaidis S., Kosmidis I., Papadopoulos S., Lioupi A., Gandanidou M., Gika H., Dokoumetzidis A., Theodoridis G., Mougios V. British Journal of Pharmacology. 2026 183:3 (438-452) 抗胸腺细胞球蛋白在髓消性造血干细胞移植中的PopPK与最佳药物暴露Population pharmacokinetics and optimal exposure of anti-thymocyte globulin in myeloablative hematopoietic cell transplantationGhazal H., Leuchter S., Ngo R., Kinzel M., Dabas R., DharmaniKhan P., Khan F.M., Jamani K., Li N., Kiang T.K., Storek J. Transplantation and cellular therapy. 2026 他克莫司口服混悬液在造血干细胞移植患儿中的PopPK及生物利用度研究Population pharmacokinetics and bioavailability of tacrolimus oral suspension in children with haematopoietic stem cell transplantBrstilo L., Ibarra M., Juliá A., Testard J., Salgueiro R., Mendoza A., Pérez C., Licciardone N., Marquet P., Staciuk R., Buontempo F., Schaiquevich P. British Journal of Clinical Pharmacology. 2026 92:1 (210-219) 从 AUC/MIC 到 AUCss 与 Cmin：通过模型引导米卡芬净在危重患者治疗中的精准给药的优化From AUC/MIC to AUCss and Cmin: Optimizing Micafungin Therapy in the Critically Ill through Model-Informed Precision DosingBerrah R., Saint Marcoux F., Monchaud C., Cointault O., Conseil M., Jaber S., Jung B., Woillard J.B. AAPS Journal2026 28:1 Article Number 18阿莫西林在人乳中的PopPK建模——ConcePTION 项目的一项贡献Population pharmacokinetic modelling of amoxicillin in human breast milk—A contribution from the ConcePTION projectBaklouti S., Rigourd V., Panchaud A., Nordeng H., Allegaert K., Annaert P., Huang M.-C., Monfort A., Guidi M., Gandia P. British Journal of Clinical Pharmacology. 2026重症监护病房（ICU）收治的医院获得性肺炎患者中，他唑巴坦联合哌拉西林给药的关键阈值目标达标率Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia含删失协变量和测量误差的广义线性混合模型及其在 HIV/AIDS 研究中的应用Generalized Linear Mixed Models with Censored Covariates and Measurement Errors, with Applications in HIV/AIDS StudiesGao S., Wu L. Statistics in Biosciences. 2025 17:3 (832-854)神经重症监护人群中左乙拉西坦给药方案的优化：Neuro-ARC 研究Levetiracetam Dosing Optimization in Neurocritical Care Population: Neuro-ARC StudyKharouba M., Cook A.M., Bastin M.L.T., Kutsogiannis D.J., Mahmoud S.H. Neurocritical Care. 2025 43:3 (887-901)结合人胎盘离体灌注数据与PBPK建模预测艾司西酞普兰、舍曲林和帕罗西汀在母亲及胎儿中的药物暴露Prediction of Maternal and Fetal Exposure to Escitalopram, Sertraline, and Paroxetine by Combining Human Ex Vivo Placenta Perfusion Data and Physiologically Based Pharmacokinetic ModelingPréta L.-H., Bouazza N., Foissac F., Froelicher L., Urien S., Buth V., Benaboud S., Tréluyer J.-M., Lui G. Clinical Pharmacokinetics. 2025 64:12 (1843-1854)ADC药物的上市后评估：基于模型荟萃分析和临床效用指数方法支持临床概念验证Postmarketing Assessment of Antibody–Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index ApproachAsiimwe I.G., Chtiba N., Mouksassi S., Pillai G., Peter R.M., Yuen E., Pilla Reddy V. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:11 (1810-1822)基于全身动态 PET 微剂量给药数据建立人体格列吡嗪全身药代动力学预测模型Modeling Whole-Body Dynamic PET Microdosing Data to Predict the Whole-Body Pharmacokinetics of Glyburide in HumansComin L., Marie S., Ursino M., Zohar S., Tournier N., Comets E. Clinical Pharmacokinetics. 2025 64:11 (1709-1722)家庭接触者中 SARS-CoV-2 检测的时间动态：首次阳性检测时间、症状出现时间与病毒载量峰值时间的差异Temporal Dynamics of SARS-CoV-2 Detection in Household Contacts: Divergences Between Time to First Positive Test, Symptom Onset, and Maximum Viral Load成人肺移植受者术后早期霉酚酸PopPK及贝叶斯评估Population pharmacokinetics of mycophenolic acid and Bayesian estimator in lung transplant adults recipients in the early post-transplant period抗中性粒细胞胞浆抗体（ANCA）相关性血管炎中利妥昔单抗诱导与维持治疗方案的比较：基于真实世界患者 ANCA 及丙种球蛋白水平的PK/PD分析Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patientspH 值对德拉沙星抗大肠杆菌等基因株抗菌活性的影响：针对不同染色体和质粒介导的氟喹诺酮类耐药机制的研究Effect of pH on antimicrobial activity of delafloxacin against Escherichia coli isogenic strains carrying diverse chromosomal and plasmid-mediated fluoroquinolone resistance mechanisms头孢唑林在儿科心脏手术患者中作为预防用药的PopPK研究Population pharmacokinetics of cefazolin administered as prophylaxis in paediatric patients undergoing cardiac surgery比较 COVID-19 疫苗接种后未感染者和康复者随时间变化的中和抗体活性Comparing neutralizing antibody activity over time between naïve and convalesced COVID-19 vaccinated individualsPillis L., Caffrey R., Chen G., Dela M., Eldevik L., Liu H., McConnell J.P., Shabahang S., Varvel S.A. Scientific reports. 2025 15:1 (34800-)泼尼松龙在系统性红斑狼疮患者中的PopPK建模：暴露量与疾病活动度分析Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity利妥昔单抗治疗多发性硬化症临床预试验中的PK-PD建模：迈向个性化给药间隔的研究Pharmacokinetic–pharmacodynamic modelling in a clinical pilot study of rituximab in multiple sclerosis: Towards personalized dosing interval采用PopPK模型优化危重症难治性和超难治性癫痫持续状态患者的苯巴比妥给药方案Optimizing phenobarbital dosing in critically ill patients with refractory and superrefractory status epilepticus using a population pharmacokinetic model妊娠对囊性纤维化女性患者中 elexacaftor、tezacaftor 和 ivacaftor 药代动力学的影响Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in cystic fibrosis womenMagnas P., Bouazza N., Foissac F., Froelicher-Bournaud L., Lui G., Carlier N., Da Silva J., Fesenbeckh J., Kanaan R., Honoré I., Martin C., Treluyer J., Tsatsaris V., Burgel P., Benaboud S. Journal of Cystic Fibrosis. 2025 24 Supplement 2 (S279a-S280)HIV 感染者中比克替拉韦的群体药代动力学：真实世界研究Population pharmacokinetics of bictegravir in real-world people with HIV社区获得性肺炎重症患者经持续输注高剂量头孢吡普后的肺内浓度研究Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia血管紧张素 II/血管紧张素 I 比值作为接受依那普利治疗的健康成年受试者和心力衰竭儿童患者群体建模的一项新的药效学参数Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with EnalaprilSteichert M., Cawello W., Burckhardt B.B., Suessenbach F.K., Laeer S. Pharmaceutics. 2025 17:10 Article Number 1345精确调整达托霉素给药剂量：3 种、2 种、1 种及 0 浓度取样方案比较Precision Daptomycin Dosing: Comparison of 3-, 2-, 1-, and 0-Concentration Sample StrategiesGiuliano S., Pai M.P., Angelini J., Flammini S., Martini L., Baraldo M., Tascini C. Pharmacotherapy. 2025 45:9 (540-546)针对接受肾脏替代治疗的危重患者的美罗培南和哌拉西林/他唑巴坦优化给药方案Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapyRoberts J.A., Ulldemolins M., Liu X., et al. Intensive Care Medicine. 2025 51:9 (1628-1640)基于PopPK模型优化利奈唑胺给药方案：针对疑似或确诊革兰阳性菌败血症的血液肿瘤患者Population Pharmacokinetic Model-Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram-Positive SepsisZavřelová A., Merdita S., Žák P., Radocha J., Víšek B., Lánská M., Maláková J., Michálek P., Slanař O., Šíma M. Clinical and Translational Science. 2025 18:9 Article Number e70346IgG 编码 mRNA的多尺度机理药代动力学—毒代动力学（PK-TK）建模在基础研究到临床的应用：以抗 Claudin 18.2 抗体为例Bench to Bedside Modeling of mRNA Encoding IgG Using a Multiscale Mechanistic Pharmacokinetic-Toxicokinetic (PK-TK) Model: A Case Study With Anti-Claudin 18.2Desai D.A., Cristofoletti R. Clinical and Translational Science. 2025 18:9 Article Number e70356使用 SVG-101 群体药动学模型评估其合理的剂量选择Application of population pharmacokinetic modeling of SVG-101 to evaluate proper dose selectionMo K.H., Chae D., Jung Y.S., Jin B.H., Keum D.H., Choi M.K., Cha J.S., Park M.S., Kim C.O. Translational and Clinical Pharmacology. 2025 33:3 (156-167)2 型糖尿病患者代谢年龄和实际年龄vs碘海醇药代动力学的相关性Correlation of Metabolic Age & Calendar Age to Iohexol Pharmacokinetics in Patients With Type 2 DiabetesAlikhani R., Hooper L., Matvekas A., Waltje A., Rothberg A., Pai M. Clinical Pharmacology in Drug Development. 2025 14 Supplement 1 (6-7)通过群体PK/PD模拟评估替格瑞洛给药剂量中断及恢复治疗（含或不含负荷剂量）的效果Evaluation of the Effect of Ticagrelor Dose Interruption and Treatment Resumption with or without Bolus Doses Through Population PK/PD SimulationMatsui H., Pham L.T.T., Adane E. European Journal of Drug Metabolism and Pharmacokinetics. 2025 50:5 (409-418)缬更昔洛韦预防巨细胞病毒感染的目标达成情况Target attainment of valganciclovir prophylaxis against cytomegalovirusWenker S., Van Hasselt C., Moes D., Märtson A. British Journal of Clinical Pharmacology. 2025 91 Supplement 1 (8-9)胺碘酮对心脏手术后患者中阿哌沙班药物暴露的影响：一项群体药代动力学研究Effect of Amiodarone on Apixaban Exposure in Patients after Cardiac Surgery—A Population Pharmacokinetic StudyMorath B., Foerster K.I., Chiriac U., Zaradzki M., Hoppe-Tichy T., Schrey D., Burhenne J., Czock D., Karck M., Haefeli W.E., Wicha S.G. Clinical Pharmacokinetics. 2025 64:8 (1191-1201)非甾体抗炎药在山地超级越野跑者干血斑中的定量分析：PK模型对结果解读的贡献Quantitative analysis of nonsteroidal anti-inflammatory drugs in dried blood spot from mountain ultra-trail runners. Contribution of pharmacokinetic models for the interpretation of the resultsMashal M.S., Guitton J., Sallet P., Bourguignon L., Machon C. Drug Testing and Analysis. 2025 17:6 (825-833)比较不同胰岛素类型的疗效：健康受试者葡萄糖钳夹效应的PK-PD建模Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy VolunteersChang Y.C., Jusko W.J. Journal of Clinical Pharmacology. 2025 65:8 (999-1010)评估多重插补算法对PK模型性能的影响：一项基于模拟的研究Assessing the Impact of Multiple Imputation Algorithms on Pharmacokinetic Model Performance: A Simulation-Based StudyDuflot T., Fayette L., Konecki C., Seurat J., Feliu C., Scala-Bertola J., Djerada Z.AAPS Journal. 2025 27:4 Article Number 77量化影响常染色体显性肾小管间质肾病进展速度和严重程度的临床及遗传因素Quantifying clinical and genetic factors influencing rate and severity of autosomal dominant tubulointerstitial kidney disease progressionRamesh S.S., Rogge M., Kidd K.O., Williams A.H., Yoon D.Y., Roignot J., Blakeslee K., Bleyer A.J., Kim S. Journal of Pharmacokinetics and Pharmacodynamics. 2025 52:4 Article Number 41甲氨蝶呤的治疗药物监测、PopPK建模及在儿童急性淋巴细胞白血病患者高剂量给药的外部验证Therapeutic Drug Monitoring, Population Pharmacokinetics Models, and External Validation of High-Dose Methotrexate in Pediatric Acute Lymphoblastic LeukemiaMaximova N., Calabrò P.F., Cangialosi A., Di Paolo A. Chemotherapy. 2025 70:3 (109-118)危重症儿童尿液生物标志物与头孢吡肟治疗目标达成的关联研究Urinary Biomarkers and Attainment of Cefepime Therapeutic Targets in Critically Ill ChildrenDownes K.J., Sharova A., Amajor V., Gianchetti L., Himebauch A.S., Fitzgerald J.C., Zuppa A.F. Pediatric Infectious Disease Journal. 2025 44:8 (749-754)Andalusian马体内静脉注射对乙酰氨基酚及其代谢物后的群体药代动力学和临床评估研究Population pharmacokinetics and clinical evaluation of intravenous acetaminophen and its metabolites in Andalusian horses预测妊娠期间他克莫司的游离浓度Predicting Unbound Tacrolimus Concentrations during PregnancyLeino A., Wilson N.K., Kataria A.D., Hebert M.F. American Journal of Transplantation. 2025 25:8 Supplement 1 (S204-)AEROfen：一项 I 期临床、开放标签、随机交叉研究方案，通过PK模型评估健康受试者中雾化芬太尼的给药效率—比较面部与鼻内给药途径AEROfen: protocol for a phase I, open-label, randomised crossover study evaluating the efficiency of nebulised fentanyl in healthy volunteers - comparing facial versus intranasal administration via pharmacometric modellingFollet C., Dumont A., Roussel M., Gillibert A., Boedard C., Quillard M., Ruault S., Vallin F., Donnadieu N., Nunes Ferreira D., Pereira T., Joly L.-M., Lvovschi V., Duflot T. BMJ Open. 2025 15:7 Article Number e091125超越线性模型的浓度- QT 分析Beyond the linear model in concentration‑QT analysisGéraldine Cellière, Andreas Krause, Guillaume Bonnefois, Jonathan Chauvin. Journal of Pharmacokinetics and Pharmacodynamics. (2025) 52:311型干扰素介导的系统性红斑狼疮炎症的综合机制模型An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus ErythematosusVolkova A., Sokolov V., Tettamanti F., Verma M., Ugolkov Y., Peskov K., Tang W., Kimko H. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:7 (1225-1235)PK/PD建模与蒙特卡洛模拟预测接受（缬）更昔洛韦治疗的儿科移植受者的巨细胞病毒载量Pharmacokinetic/Pharmacodynamic Modelling and Monte Carlo Simulations to Predict Cytomegalovirus Viral Load in Pediatric Transplant Recipients Treated with (val) GanciclovirKoloskoff K., Franck B., Benito S., Welzel J., Autmizguine J., Theoret Y., Briand A., Ovetchkine P., Woillard J.-B. Clinical Pharmacokinetics. 2025 64:7 (1061-1069)沙特阿拉伯儿童肝移植术后早期他克莫司药代动力学的一项回顾性分析A retrospective analysis of tacrolimus pharmacokinetic in Saudi paediatric patients in early post-liver transplantation periodAlghanem A., Joharji H., Garaween N., Alenazi H., Alsaleh N.A., Broering D., Alshagrani M., Alhassan F., Albassam A.A., Alsultan A., Alsmari A. Pediatrics and Neonatology. 2025 66:4 (368-374)利用纵向患者报告结局轨迹预测非小细胞肺癌生存期Leveraging Longitudinal Patient-Reported Outcome Trajectories to Predict Survival in Non–Small Cell Lung Cancer理解与优化剂量探索：从剂量模拟到剂量估算Understanding and Streamlining Dose Finding: From Dose Simulation to Dose EstimationBräm D., Bachmann F., Schropp J., Gotta V., Steffens B., van den Anker J., Pfister M., Koch G. Journal of Clinical Pharmacology. 2025 65:6 (731-741)基于模型的方法评估抗药物抗体对生物制剂药物暴露的影响：以 CD3 T 细胞双特异性抗体赛必妥单抗为例A Model-Based Approach to Evaluate Anti-Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T-Cell Bispecific CibisatamabSanchez J., Pierrillas P.B., Frey N., Lotz G.P., Jönsson S., Friberg L.E., Frances N. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:6 (1065-1076)基于治疗药物监测, 考察阿米卡星在教学医院患者中的群体药代动力学Therapeutic Drug Monitoring-Based Population Pharmacokinetics of Amikacin in Patients at a Teaching HospitalSteffens N.A., Zimmermann E.S., Azeredo F.J., Linden R., Finatto L.J., Hahn R.Z., Schwarzbold A.V., Pacheco L.S., Brucker N. Antibiotics. 2025 14:6 Article Number 531辅助靶点的药效学评估：低分子量 PBP7/8 对β-内酰胺类药物抗碳青霉烯耐药鲍曼不动杆菌活性的影响Pharmacodynamic Evaluation of Adjuvant Targets: Low Molecular Weight PBP7/8 Effects on β-Lactam Activity Against Carbapenem-Resistant Acinetobacter BaumanniiHo B.M., Jin J., Sanborn J.T., Nguyen T.D., Singh N., Cheng C., Nasief N.N., Carlino-MacDonald U., Tsuji B.T., Zhao Y., Chen L., Moya B., Russo T.A., Smith N.M.Pharmaceuticals. 2025 18:6 Article Number 918WS02.06 Elexacaftor/tezacaftor/ivacaftor在 2 至 5 岁儿童中的药代动力学及行为障碍发生情况WS02.06Elexacaftor/tezacaftor/ivacaftor pharmacokinetics and occurrence of behavioural disorders in children aged 2 to 5 years oldTruong N.H., Benaboud S., Chouchana L., Bonnel A.-S., Barboura M., Bouazza N., Gautier S., Rouillon S., Froelicher-Bournaud L., Bihouee T., Bui S., Treluyer J.-M., Gaudelus I.S., Foissac F., Modul-CF research group. Journal of Cystic Fibrosis. 2025 24 Supplement 1 (S5-)老年群体中皮下注射与静脉注射头孢曲松的药代动力学：PhASAge 研究Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone in an Older Population: The PhASAge StudyRoubaud-Baudron C., Fauchon H., Stanke-Labesque F.,et al. Open Forum Infectious Diseases. 2025 12:6 Article Number ofaf313感染后期植入的 SIV 前病毒存在于寿命较短的 CD4+ T 细胞中SIV proviruses seeded later in infection are harbored in short-lived CD4+ T cells一箭多雕：用于多适应症的肠溶型霉酚酸钠的PopPK模型及贝叶斯估算Killing several birds with one stone: A multi-indication population pharmacokinetic model and Bayesian estimator for enteric-coated mycophenolate sodiumFromage Y., Sayadi H., Koloskoff K., Marquet P., Labriffe M., Monchaud C., Woillard J.-B. British Journal of Clinical Pharmacology. 2025 91:5 (1396-1408)通过PopPL分析优化 1-3 级肥胖患者静脉注射利多卡因的给药方案Dosing optimisation of intravenous lidocaine in patients with class 1–3 obesity by population pharmacokinetic analysisTognolini A.R., Liu X., Pandey S., Roberts J.A., Wallis S.C., Jackson D., Eley V.A. Anaesthesia. 2025 80:5 (511-521)用于考察阿替洛尔与美托洛尔在营养不良大鼠体内吸收的迷你PBPK模型Minimal Physiologically-Based Pharmacokinetic Modeling of Atenolol and Metoprolol Absorption in Malnourished RatsKir F., Sahin S., Jusko W.J. European Journal of Drug Metabolism and Pharmacokinetics. 2025 50:3 (251-263) Article Number e115Elexacaftor/Tezacaftor/Ivacaftor在囊性纤维化儿科患者中的群体药代动力学研究Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic FibrosisTruong N.H., Benaboud S., Bouazza N., Barboura M.,et al. Clinical and Translational Science. 2025 18:5 Article Number e70245比较妊娠妇女在惊厥前期使用 75 mg与 150 mg阿司匹林的效果Comparing 75mg vs 150mg aspirin in pregnancy women at risk of preeclampsiaVinogradov R., Kavanagh O.N., Kamali F., Robson S. American Journal of Obstetrics and Gynecology. 2025 232:5 (e189-e190)克林霉素与利福平联合用药的剂量及给药途径Dosing and route of administration of clindamycin given in combination with rifampicinMagréault S., Berrah R., Kerroumi Y., Mimram L., Salmon D., Goulenok T., de la Selle A., Lefort A., Marmor S., Helali N.H., Zeller V., Jullien V. Clinical Microbiology and Infection. 2025 31:5 (832-838)舒更葡糖或新斯的明逆转维库溴铵诱导犬神经肌肉阻滞的速度：随机临床试验与药理学建模Speed of reversal by sugammadex or neostigmine after vecuronium-induced neuromuscular block in dogs: Randomized clinical trial and pharmacological modelingMartin-Flores M., Lorenzutti A.M., Markmann A.D., Araos J., Campoy L. Veterinary Anaesthesia and Analgesia. 2025 52:3 (328-337)阿昔洛韦及其主要代谢产物 9-羧甲氧基甲基鸟嘌呤在早期肝移植受者中的群体药代动力学及伐昔洛韦的安全性评估Population pharmacokinetics of aciclovir and its major metabolite 9-carboxymethoxymethylguanine and safety profile of valaciclovir in early liver transplant recipientsKably B., Briard M., Francoz C., Roux O., Houhou N., Mackiewicz V., Peytavin G., Durand F., Lê M.P. Journal of Antimicrobial Chemotherapy. 2025 80:5 (1302-1308)一种用于治疗慢性乙型肝炎的衣壳蛋白装配调节剂作用的多尺度模型A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B左乙拉西坦药代动力学在真实世界中的患者间变异性Real-world interpatient variability in the pharmacokinetics of levetiracetamChykharivska A., Kagan L., Wagner M., Brunetti L. Fundamental and Clinical Pharmacology. 2025 39:2 Article Number e13059接受连续性肾脏替代治疗的危重患者是否需要调整头孢洛林给药剂量？基于回顾性数据的头孢洛林PopPK模型及目标达成概率分析的剂量模拟Do Critically Ill Patients Undergoing Continuous Renal Replacement Therapy Require Ceftaroline Dosage Adjustments? Ceftaroline PopPK Model and Dosage Simulations with the Probability of Target Attainment Analysis Based on Retrospective DataAdamiszak A., Pietrzkiewicz K., Bartkowska-Śniatkowska A., Smuszkiewicz P., Kusza K., Grześkowiak E., Bienert A. Antibiotics. 2025 14:4 Article Number 347胶质母细胞瘤患者中帕米帕利总药量及游离药量的PopPK建模：药物处置机制解析与给药方案优化Population Pharmacokinetic Modeling of Total and Unbound Pamiparib in Glioblastoma Patients: Insights into Drug Disposition and Dosing OptimizationWickramasinghe C., Kim S., Jiang Y., Bao X., Yue Y., Jiang J., Hong A., Sanai N., Li J. Pharmaceutics. 2025 17:4 Article Number 524美罗培南在严重细菌感染患者中的群体药动学与基于模型的给药方案优化Meropenem population pharmacokinetics and model-based dosing optimisation in patients with serious bacterial infectionMurínová I., Švidrnoch M., Gucký T., Rezáč D., Hlaváč J., Slanar O., Šíma M. European Journal of Hospital Pharmacy. 2024 31:3 (253-258)万古霉素在越南儿科患者治疗药物监测中的PopPK建模及中点浓度便捷采样Population Pharmacokinetic Modeling and Convenient Sampling of Midpoint Concentration for Therapeutic Drug Monitoring of Vancomycin in Vietnamese Pediatric PatientsHai L.B., Kien P.C., Dua N.T., Hao N.T., Hung V.M., Hai N.T., Le J., Huong N.T.L. Pharmaceutical Sciences Asia. 2024 51:3 (241-249)影响万古霉素谷浓度的因素：沙特非重症监护患者的PopPK模型Factors Affecting Vancomycin Trough Concentration; a Population Pharmacokinetic Model in Non-Critical Care Saudi PatientsOrvacabtagene Autoleucel, 一种自体 BCMA 导向的CAR-T 细胞产品在治疗复发/难治性多发性骨髓瘤患者中的PopPK研究Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple MyelomaHu H., Li Y., Piasecki J., Hosseyni D., Yan Z., Liu X., Ogasawara K., Zhou S., Cheng Y. Clinical Cancer Research. 2025 31:6 (1163-1171)建模分析表明，奈玛特韦-利托那韦治疗后出现的 SARS-CoV-2 病毒反弹，是由靶细胞得以保留与病毒清除不彻底共同导致的Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearancePhan T., Ribeiro R.M., Edelstein G.E., Boucau J., et al.Journal of Virology. 2025 99:3用于癌症药物PK-PD建模与模拟的多器官芯片Multiorgan-on-a-chip for cancer drug pharmacokinetics-pharmacodynamics (PK-PD) modeling and simulationsMohammed A.E., Kurucaovalı F., Okvur D.P. Journal of Pharmacokinetics and Pharmacodynamics. 2025 52:1 Article Number 1NX210c多肽在健康老年受试者中的安全性、耐受性及PK-PD关系研究：一项随机、安慰剂对照、双盲、多剂量递增试验Safety, Tolerability and Pharmacokinetic-Pharmacodynamic Relationship of NX210c Peptide in Healthy Elderly Volunteers: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study卡泊芬净在接受体外膜氧合治疗的危重患者中的PopPK研究——ASAP ECMO 研究Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation—an ASAP ECMO studyAbdul-Aziz M.H., Diehl A., Liu X., Cheng V., Corley A., Gilder E., Levkovich B., McGuinness S., Ordonez J., Parke R., Pellegrino V., Wallis S.C., Fraser J.F., Shekar K., Roberts J.A. Antimicrobial Agents and Chemotherapy. 2025 69:2肾功能不全患者中哌拉西林剂量调整：无论是否接受肾脏替代治疗, 均需增加达到目标暴露量Dosing of Piperacillin in Altered Renal Function with and without Renal Replacement Therapy for Required Increased ExpositionSurat G., Dohmann E., Scherf-Clavel O., Kurlbaum M., Hagel S. Open Forum Infectious Diseases2025 12 Supplement 1 (S798-)重症成人鲍曼不动杆菌感染患者口服米诺环素的PK模型Phamacokinetic Model of Oral Minocycline in Critically Ill Adult Patients with Acinetobacter baumannii InfectionKoumaki V., Athanassa Z., Valsami G., Papakyriakopoulou P., Saitani E.-M., Marques S., Manioudaki S., Sakagianni A., Dokoumatzidis A., Tsakris A. Open Forum Infectious Diseases. 2025 12 Supplement 1 (S801-)使用容积吸收微量采样法研究多器官功能障碍综合征危重患儿中的万古霉素群体药代动力学Vancomycin Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children with Multiple Organ Dysfunction SyndromeShiau J., Amajor V., Rhodes N.J., Zuppa A., Downes K.J., Takyi-Williams J., Wen B., Scheetz M.H. Open Forum Infectious Diseases. 2025 12 Supplement 1 (S788-S789)粒细胞集落刺激因子的群体PK-PD建模以优化 CD34+细胞采集的给药剂量与给药时机Population Pharmacokinetic–Pharmacodynamic Modeling of Granulocyte Colony-Stimulating Factor to Optimize Dosing and Timing for CD34+ Cell HarvestingXu Jiang, Jun Seok Cha, Byung Hak Jin, Choon Ok Kim, Dongwoo Chae. Clinical and Translational Science, 2025; 18:e70121基于PopPK模型，为接受血液透析的肥胖患者群体制定万古霉素负荷剂量个体化给药方案Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic modelPolášková L., Hartinger J.M., Murínová I., Michálek P., Slanař O., Šíma M. Journal of Chemotherapy. 2025 37:2 (121-129)考虑个体间变异的低维神经常微分方程在 Monolix 和 NONMEM 中的实现Low-dimensional neural ordinary differential equations accounting for inter-individual variability implemented in Monolix and NONMEMBräm D.S., Steiert B., Pfister M., Steffens B., Koch G. CPT: Pharmacometrics and Systems Pharmacology. 2025 14:1 (5-16)瑞德西韦及其代谢物在健康受试者和肾功能不全患者中的药代动力学模拟Pharmacokinetic simulations for remdesivir and its metabolites in healthy subjects and patients with renal impairment群体PK/PD分析证实 SB16 与参比药物地舒单抗具有生物相似性Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab肠溶阿司匹林胶囊与片剂在健康受试者群体中的PK-PD研究Population Pharmacokinetic and Pharmacodynamic Modeling of Enteric-Coated Aspirin Capsule and Tablet Formulations in Healthy Subjects结核病治疗中剂量精准的重要性The importance of getting the dose right in the treatment of tuberculosis瑞舒伐他汀和依折麦布联合用药导致肠肝循环的群体PK-PD研究Population Pharmacokinetics and Pharmacodynamics with Enterohepatic Recirculation of Co-Medication of Rosuvastatin and Ezetimibe在美国未感染 HIV 的成人中单独使用抗HIV-1 单克隆抗体 PGT121.414.LS，及与VRC07-523LS 联合给药的安全性、耐受性、药代动力学及中和活性研究（项目编号HVTN 136/HPTN 092）：一项首次人体、开放标签、随机对照的 1 期临床试验Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialEdupuganti S., Hurt C.B., Stephenson K.E., Huang Y., et al.The Lancet HIV. 2025 12:1 (e13-e25)恩诺沙星在治疗肉鸡大肠杆菌病中的PK、PD预测指标及蒙特卡洛模拟研究Pharmacokinetics, pharmacodynamic efficacy prediction indices, and Monte Carlo simulations of enrofloxacin for the treatment of colibacillosis in broiler chickens卡铂在犬类中的PopPK建模及其临床剂量调整Population pharmacokinetics modelling for clinical dose adjustment of carboplatin in dogsBéguin J., Mahfoudhi S., Uzel M., Rostang A., Ibish C., Ferran A.A., Pelligand L., Hulin A., Kohlhauer M. BMC Veterinary Research. 2024 20:1 Article Number 575Development of a Population Pharmacokinetic Gabapentin Model Leveraging Therapeutic Drug Monitoring ConcentrationsAl-Zubaydi F., Wassef A., Kagan L., Brunetti L. Pharmaceutics. 2024 16:12 Article Number 1514阿莫西林对犬类假中间葡萄球菌PK-PD评价Pharmacokinetics and Pharmacodynamics Evaluation of Amoxicillin Against Staphylococcus pseudintermedius in DogsJeong J.-S., Kim J.-W., Kim J.-H., Kim C.-Y., Chung E.-H., Boo S.-Y., Lee S.-H., Ko J.-W., Kim T.-W. Pathogens. 2024 13:12 Article Number 1121膳食和制剂对耐药性发育性及癫痫性脑病患儿体内大麻二酚全身暴露的影响Impact of food and formulation on cannabidiol systemic exposure in children with drug-resistant developmental and epileptic encephalopathiesBrstilo L., Reyes G., Ibarra M., Cáceres Guido P., Bressan I., Marin M.N., Delaven S.F., Agostini S., Pérez Montilla C., López M.E., Cresta A., García Bournissen F., Schaiquevich P., Caraballo R. Epilepsia. 2024 65 Supplement 1 (492-)基于模型荟萃分析建立复方口服避孕药突破性出血模型Development of breakthrough bleeding model of combined-oral contraceptives utilizing model-based meta-analysisChen H., Chun D., Lingineni K., Guzy S., Cristofoletti R., Hoechel J., Jiao T., Cicali B., Vozmediano V., Schmidt S. CPT: Pharmacometrics and Systems Pharmacology. 2024 13:11 (2016-2025)静脉注射免疫球蛋白在治疗各类免疫系统疾病患者中的PopPK模型Population Pharmacokinetic Model of Intravenous Immunoglobulin in Patients Treated for Various Immune System DisordersLee J.L., Mohamed Shah N., Makmor-Bakry M., Islahudin F., Alias H., Mohd Saffian S. Clinical Therapeutics. 2024 46:12 (e25-e37)持续输注哌拉西林/他唑巴坦可优化择期盆腔摘除术患者术中抗生素暴露水平Continuous infusion of piperacillin/tazobactam optimizes intraoperative antibiotic exposure in patients undergoing elective pelvic exenteration surgeryJackson D., Ulldemolins M., Liu X., Harris C., Tognolini A., Wallis S.C., Sumi C., Parker S.L., Eley V., Roberts J.A. Antimicrobial Agents and Chemotherapy. 2024 68:12接受单倍体相合干细胞移植并采用移植后环磷酰胺/环孢素 A 为基础的移植物抗宿主病预防方案的患者中，霉酚酸暴露量降低—需加强剂量调整Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis - Need for Dose IntensificationPai A.A., Panetta J.C., Bijukumar N., Renji R.M., A M., Jayaraman A., Karumathil S., Korula A., Selvarajan S., Srivastava A., Abraham A., Mathews V., George B., Kulkarni U., Balasubramanian P. Blood. 2024 144 Supplement 1 (2150-)不同剂量的甲氨蝶呤在类风湿关节炎患者中的PK-PD建模与模拟Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis研究丙泊酚作为单一药物对 2-12 岁儿童双频谱指数峰值效应时间的影响Understanding time to peak effect of propofol as sole agent on bispectral index in children aged 2–12 yearsGavel G., Koch G., Terrier A., Atkinson A., Pfister M., Erb T. Paediatric Anaesthesia. 2024 34:10 (1019-1028)替扎帕林（一种皮下注射普通肝素的替代药物）用于重度及终末期肾功能不全患者的回顾性单中心观察性研究Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study麦考酚酸酯在印度狼疮性肾炎患者群体中的PopPK及有限采样策略研究Population Pharmacokinetics and Limited Sampling Strategy of Mycophenolate Mofetil for Indian Patients With Lupus NephritisKoloskoff K., Panwar R., Rathi M., Mathew S., Sharma A., Marquet P., Benito S., Woillard J.-B., Pattanaik S. Therapeutic Drug Monitoring. 2024 46:5 (567-574)通过建模与模拟确定儿科重症监护室中美罗培南的最佳给药策略Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation给药剂量是否得当？重症儿童患者中头孢吡肟的PopPK研究Are We Dosing Correctly? Population Pharmacokinetics of Cefepime in Critically Ill Pediatric PatientsRolsma S., Blackman M., Beck C., Dbouk A., Morovia F., Glover F., Ess G., Dohler K., Bridges B., Choi L., Creech C.B. Journal of the Pediatric Infectious Diseases Society. 2024 13 Supplement 4 (S9-S10)评估高加索健康受试者中与体重相关的协变量对利福平PK的影响Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteersBilal M., Ullah S., Jaehde U., Trueck C., Zaremba D., Wachall B., Wargenau M., Scheidel B., Wiesen M.H.J., Gazzaz M., Chen C., Büsker S., Fuhr U., Taubert M., Dokos C. European Journal of Clinical Pharmacology. 2024 80:9 (1271-1283)采用非线性混合效应模型对肥胖血液透析患者庆大霉素个体药代动力学参数进行估算Individual pharmacokinetic parameter estimation of gentamicin in an obese hemodialysis patient using non-linear mixed effect modelLee H., Yoon S., Chung J.Y. Translational and Clinical Pharmacology. 2024 32:3 (150-158)利用定量药理学评估患者友好的伊维菌素 CHILD-IVITAB 在体重≥15 kg 和 <15 kg 儿童中的给药剂量Pharmacometrics to Evaluate Dosing of the Patient-Friendly Ivermectin CHILD-IVITAB in Children ≥ 15 kg and <15 kgGolhen K., Buettcher M., Huwyler J., van den Anker J., Gotta V., Dao K., Rothuizen L.E., Kobylinski K., Pfister M. Pharmaceutics. 2024 16:9 Article Number 1186Elexacaftor/tezacaftor/ivacaftor 药代动力学与 2 至 5 岁儿童行为障碍的发生情况的研究Elexacaftor/tezacaftor/ivacaftor pharmacokinetics and occurance of behavioral disorders in children aged 2 to 5Truong N., Benaboud S., Chouchana L., Bonnel A., Barboura M., Bouazza N., Gautier S., Rouillon S., Froelicher-Bournaud L., Bihouee T., Bui S., Treluyer J., Sermet-Gaudelus I., Foissac F. Journal of Cystic Fibrosis. 2024 23 Supplement 2 (S277-S278)重症患者需增加头孢哌酮负荷剂量：一项采用PK建模评估推荐负荷剂量的回顾性研究Loading Dose of Ceftazidime Needs to Be Increased in Critically Ill Patients: A Retrospective Study to Evaluate Recommended Loading Dose with Pharmacokinetic ModellingLaunay M., Ollier E., Kably B., Le Louedec F., Thiery G., Lanoiselée J., Perinel-Ragey S. Antibiotics. 2024 13:8 Article Number 756达沙替尼在健康受试者中的PopPK研究Population Pharmacokinetics of Dasatinib in Healthy SubjectsHassouneh W.B., Al-Ghazawi M.A., Saleh M.I., Najib N. Pharmaceuticals. 2024 17:6 Article Number 671WS15.03 Elexacaftor/tezacaftor/ivacaftor 在囊性纤维化儿科患者中的PopPK研究WS15.03 Elexacaftor/tezacaftor/ivacaftor population pharmacokinetics in paediatric patients with cystic fibrosisTruong N.H., Benaboud S., Bardin E., et al. Journal of Cystic Fibrosis. 2024 23 Supplement 1 (S28-)慢性髓性白血病患者体重指数与血浆中伊马替尼浓度的关系，并采用PK引导的给药策略减轻其临床影响Relationship of body mass index and plasma imatinib levels in CML patients and mitigation of clinical impact using PK-guided dosing strategyMaroselli P., Fanciullino R., Colle J., Farnault L., Rocher P., Venton G., Costello R., Ciccolini J. Journal of Clinical Oncology. 2024 42:16 Supplement延长纳武利尤单抗给药间隔：在未筛选癌症患者中开展基于模型的模拟Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patientsPuszkiel A., Bianconi G., Pasquiers B., Balakirouchenane D., Arrondeau J., Boudou-Rouquette P., Bretagne M.-C., Salem J.-E., Declèves X., Vidal M., Kramkimel N., Guegan S., Aractingi S., Huillard O., Alexandre J., Wislez M., Goldwasser F., Blanchet B. British Journal of Cancer. 2024 130:11 (1866-1874)RPEM：随机蒙特卡洛参数期望最大化算法RPEM: Randomized Monte Carlo parametric expectation maximization algorithmChen R., Schumitzky A., Kryshchenko A., Nieforth K., Tomashevskiy M., Hu S., Garreau R., Otalvaro J., Yamada W., Neely M.N. CPT: Pharmacometrics and Systems Pharmacology. 2024 13:5 (759-780)肺移植受者进行伊沙康唑治疗药物监测的理论依据The Rationale for Therapeutic Drug Monitoring of Isavuconazole in a Lung Transplant RecipientZajacova A., Sima M., Havlin J., Klapkova E., Lischke R., Slanar O., Dvorackova E. Journal of Heart and Lung Transplantation. 2024 43:4 Supplement (S644-S645)Lumacaftor/Ivacaftor 在囊性纤维化儿科患者中的PopPK：迈向个体化治疗的第一步Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized TherapyBouazza N., Urien S., Foissac F., Choupeaux L., et al. Clinical Pharmacokinetics. 2024 63:3 (333-342)赖诺普利在高血压的儿童和正常至轻度肾功能受损的青少年的PopPK研究Population pharmacokinetics of lisinopril in hypertensive children and adolescents with normal to mildly reduced kidney functionSandra L., Degraeuwe E., De Bruyne P., De Baere S., Croubels S., Van Bocxlaer J.F.P., Raes A., Vande Walle J., Gasthuys E., Vermeulen A. British Journal of Clinical Pharmacology. 2024 90:2 (504-515)基于模型的临床前试验心血管安全性评估与转化教程A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trialsKulesh V., Vasyutin I., Volkova A., Peskov K., Kimko H., Sokolov V., Alluri R. CPT: Pharmacometrics and Systems Pharmacology2024 13:1 (5-22)提高奥拉帕利的药物暴露量以优化不良反应管理Improving olaparib exposure to optimize adverse effects managementSterlé M., Puszkiel A., Burlot C., Pereira E., Bellesoeur A., De Percin S., Beinse G., Fumet J.-D., Favier L., Niogret J., Blanchet B., Royer B., Bengrine-Lefevre L., Schmitt A. Therapeutic Advances in Medical Oncology. 2024 16疑似急性肾移植排斥反应：甲基泼尼松龙治疗下他克莫司的药代动力学研究Suspicious of Acute Kidney Graft Rejection: Tacrolimus Pharmacokinetics Under Methylprednisolone TherapyBidu N.S., Mattoso R.J.C., Santos O.A.C.O., Alves I.A., Fernandes B.J.D., Couto R.D. Current Drug Research Reviews. 2024 16:3 (403-411)►►►往年MonolixSuite文献汇总返回搜狐，查看更多

2026-02-11

·百度百家

光催化：从同一分子岔路口，驶向环丙烷与环丁烷

在分子世界里修建环状道路。传统的施工队往往只能修建特定大小的环——要么是紧张的三元环（环丙烷），要么是稍大的四元环（环丁烷），而且工具和路线相对固定。化学家们一直梦想着能有一个智能的“交通枢纽”，能从同一个起点出发，根据指令，精准地通往两个不同的环状目的地。最近，韩国首尔大学Seung Youn Hong教授团队的研究，将这个梦想照进了现实。他们利用光催化技术，指挥简单的烯烃分子，通过巧妙的反应设计，实现了向环丙烷和环丁烷的发散性合成。这就像手握同一套“分子积木”，仅通过微调反应条件，就能选择性地搭建出两种结构迥异、却都极具价值的小碳环。为什么小碳环如此重要？环丙烷和环丁烷，是有机分子中独特而刚性的“小个子”。它们虽小，能量却大。在药物分子中引入这样的刚性环，就像为柔软的分子链装上“骨骼支架”，能精确固定官能团的空间朝向，从而更有效地与生物靶点结合。它们也常被用作巧妙的结构替代单元，用以改善药物的代谢稳定性、调节溶解性。从抗癌药到抗生素，再到农药和先进材料，这些小碳环的身影无处不在。传统方法的“单行道”困境过去，合成这两种环的主要方法是环加成。合成三元环常用[2+1]策略，如烯烃加一个碳原子（C1合成子）；合成四元环则多用[2+2]策略，即两个烯烃（C2合成子）拼接。这些方法如同“单行道”，路线一旦选定，产物环的大小、取代模式便几乎被底物本身锁死，缺乏后期灵活调整的余地。化学家们需要更通用、更灵活的合成工具箱。光催化开辟“智能岔路口” Seung Youn Hong团队的突破，核心在于创造了一个具有“双重性格”的关键中间体。他们让烯烃与一种特殊的碘甲基噻蒽鎓盐，在光催化作用下结合，生成了一个名为“3-碘代烷基噻蒽鎓”的中间体。这个中间体，正是通往两个目的地的“交通枢纽”。它内部蕴含着两种反应潜能，而化学家通过选择不同的“碱”作为指挥信号，就能引导它驶向完全不同的路径：路径一：[2+1]环化，驶向环丙烷。当使用像LDA（二异丙基氨基锂）这样的强碱时，中间体会迅速脱去一个质子，变身成一种高活性的“噻蒽鎓叶立德”。这个叶立德分子随即发生分子内的[2+1]环合，高效构建起环丙烷骨架，并带上一个极具价值的噻蒽鎓盐“手柄”。这个“手柄”非同小可——它能通过后续的偶联或自由基反应，被精准地替换成含氮、含碳等多种官能团，从而快速构建出结构多样的1，2-双官能团化环丙烷库。路径二：[2+1+1]环化，驶向环丁烷。当切换为碳酸铯这类更温和的碱时，故事走向截然不同。中间体不会内关环，而是先与另一分子“亚甲基化前亲核试剂”（如腈类化合物）结合，形成一个新的扩展中间体。紧这个新中间体发生一次[2+1+1]环化反应——相当于将原有的烯烃双键与新增的碳单元重新组装，最终构建出环丁烷环，并直接得到1，2-双官能团化环丁烷。发散性合成的魅力在此刻尽显：相同的起始烯烃，相同的初始光催化步骤，仅通过改变碱这个“调控旋钮”，就能高选择性、高非对映选择性地分别获得环丙烷或环丁烷产物。这种方法对底物兼容性广，许多复杂的药物分子衍生物也能顺利参与反应，为药物先导化合物的后期结构修饰与优化提供了强大工具。不止于方法：一种合成哲学的启示这项工作的意义，远不止于提供了一个高效合成小碳环的新方法。它更展示了一种现代合成化学的深刻思想：通过对关键中间体反应性的精细调控，实现合成路径的智能发散。它让化学家从一个共同的、易于获得的前体出发，像掌控一套精密的乐高组件，有目的、可预测地构建出多个结构迥异的目标分子。这极大地提升了合成的效率和原子经济性，也大大拓展了分子结构的多样性空间。从抗抑郁药帕罗西汀中的环丁烷结构，到众多天然产物及药物活性分子中的环丙烷单元，小碳环的价值不言而喻。而光催化与发散性合成策略的结合，正为更便捷、更绿色地获取这些有价值的分子砌块打开了一扇新的大门。这不仅是实验室里的巧妙反应，更是推动新药研发、创造新型功能材料背后，那股不可或缺的基础创新力量。科学的前沿，往往就藏在这些对分子世界“交通规则”的重新构想之中。

100 项与甲磺酸帕罗西汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05375	甲磺酸帕罗西汀	N06AB05	DB00715

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
血管舒缩症	美国	Legacy Pharmacy LLC	2013-06-28
广泛性焦虑障碍	美国	Sebela Ireland Ltd.	2006-12-09
重度抑郁症	美国	Sebela Ireland Ltd.	2003-07-03
强迫症	美国	Sebela Ireland Ltd.	2003-07-03
惊恐障碍	美国	Sebela Ireland Ltd.	2003-07-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03329573 (CTgov)	临床1期	焦虑症	85	GSKT+Paroxetine (Paroxetine 40 mg, GSKT- Fed)	網壓壓艱構鑰餘獵醖遞(遞艱廠鬱遞淵淵壓齋製) = 鑰繭選築衊簾餘衊餘壓衊淵構齋窪憲觸繭淵艱 (膚願襯網鏇鬱窪鑰襯積, 艱餘獵鏇網夢獵夢觸築 ~ 繭廠淵製鏇襯範遞範餘) 更多	-	2019-08-19
NCT03329573 (CTgov)	临床1期	焦虑症	85	Paroxetine (Paroxetine 40 mg, Mississauga- Fed)	網壓壓艱構鑰餘獵醖遞(遞艱廠鬱遞淵淵壓齋製) = 製觸廠製衊顧觸淵衊選衊淵構齋窪憲觸繭淵艱 (膚願襯網鏇鬱窪鑰襯積, 遞鹽糧選構範觸齋鑰築 ~ 繭繭淵顧憲網顧積築鹹) 更多	-	2019-08-19
NCT01361308 (N30-003, CTgov)	临床3期	更年期综合症 \| 血管舒缩症	614	Placebo capsules	鹽糧糧遞憲築網鏇淵積(遞醖艱構鬱糧餘憲獵鹽) = 衊醖選顧齋鑰艱鑰選蓋觸膚廠鏇鏇艱蓋簾糧獵 (獵觸糧齋選壓遞憲鹽膚, 4.39) 更多	-	2014-05-20
NCT01101841 (CTgov)	临床3期	更年期综合症 \| 潮热 \| 血管舒缩症	570	Placebo capsules	艱艱簾網鑰衊遞鏇鑰積(願構顧齋淵鏇衊壓壓鬱) = 範範鹹獵醖製構範廠簾壓願餘醖積蓋夢製遞鑰 (餘夢憲網糧糧廠蓋鬱構, 3.96) 更多	-	2014-04-21
NCT00786188 (CTgov)	临床2期	更年期综合症 \| 潮热 \| 血管舒缩症	102	sugar pill	繭糧淵繭壓蓋糧衊遞壓(鑰觸膚艱網觸遞糧淵製) = 願襯餘醖積壓製醖鹽繭鏇築齋鏇製構壓壓積蓋 (窪憲鏇夢簾簾獵鑰構鏇, 3.67) 更多	-	2014-03-12
NCT01829919 (N30-005, CTgov)	临床1期	-	24	Brisdelle (Paroxetine Mesylate) (Brisdelle (Paroxetine Mesylate) Capsules 7.5 mg)	範構壓簾蓋膚選鬱鹽憲(網壓網壓構襯淵觸遞壓) = 製衊鏇鹽鏇淵構襯壓窪鏇選簾膚餘顧壓鑰遞壓 (鬱範範鹹願遞蓋鬱膚遞, 166.19) 更多	-	2014-02-24
NCT01829919 (N30-005, CTgov)	临床1期	-	24	Brisdelle (Paroxetine Mesylate) (Brisdelle (Paroxetine Mesylate) Capsules)	選顧築鹽鹹築窪願壓膚(願淵齋遞鹽膚鬱壓簾簾) = 選鬱積網製獵糧艱夢餘蓋製糧廠醖餘醖襯窪觸 (憲願構鬱廠築範鏇選膚, 鬱衊壓選淵鏇顧願齋衊 ~ 鹹觸觸願選鑰選簾窪憲) 更多	-	2014-02-24
NCT01829919 (Pubmed \| Clin Ther)	临床1期	-	24	LDMP 7.5 mg	觸鬱選餘顧鑰築鹹淵鬱(鏇選齋鏇夢艱膚選積範) = Most subjects (23/24 [95.8%]) experienced at least 1 treatment-emergent adverse event (AE); however, most AEs (67 events in 22/24 subjects [91.7%]) were mild, and the remainder were moderate. Seventeen subjects experienced 33 AEs that were deemed possibly or probably related to LDMP. No serious AEs were reported, and no clinically meaningful changes in laboratory values, vital signs, or ECGs were observed. 憲窪窪夢築築廠簾衊構 (壓醖鹽艱積鹹糧壓簾廠 )	-	2013-06-01